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ABSTRACT  25 
Prolactinomas are the most frequently observed pituitary adenomas and most 26 
of them respond well to conventional treatment with dopamine agonists. However, a 27 
subset of prolactinomas fails to respond to such therapies and is considered as 28 
dopamine agonist-resistant prolactinomas (DARPs). New therapeutic approaches are 29 
necessary for these tumors. TGFβ1 is a known inhibitor of lactotroph cell proliferation 30 
and prolactin secretion, and it partly mediates dopamine inhibitory action. TGFβ1 is 31 
secreted to the extracellular matrix as an inactive latent complex, and its bioavailability 32 
is tightly regulated by different components of the ´TGFβ1 system including latent 33 
binding proteins (LTBPs), local activators (Thrombospondin-1, matrix metalloproteases, 34 
integrins, among others), and TGFβ receptors. Pituitary TGFβ1 activity and the 35 
expression of different components of the TGFβ1 system, are regulated by dopamine 36 
and estradiol. Prolactinomas (animal models and humans) present reduced TGFβ1 37 
activity as well as reduced expression of several components of the TGFβ1 system. 38 
Therefore, restoration of TGFβ1 inhibitory activity represents a novel therapeutic 39 
approach to bypass dopamine action in DARPs. The aim of this review is to summarize 40 
the large literature supporting TGFβ1 important role as a local modulator of pituitary 41 
lactotroph function; as well to provide recent evidence of the restoration of TGFβ1 42 
activity as an effective treatment in experimental prolactinomas.   43 
 44 
45 
Page 2 of 27
3 
 
      Pituitary tumors  46 
 47 
Pituitary tumors are commonly benign, slow growing adenomas and account for 48 
10-15% of all intracranial neoplasms (Farrell 2006; Melmed 2015).  The prevalence of 49 
these tumors is relatively high in the general population, with approximately 77 cases 50 
per 100.000 (Daly et al. 2009; Fernandez et al. 2010), and studies of autopsy 51 
specimens identified up to a 20% prevalence of clinically occult pituitary adenomas 52 
(Ezzat et al. 2004).  53 
Despite their benign features pituitary tumors can cause considerably morbidity 54 
due to both hypersecretion of pituitary trophic hormones and excessive tumor growth 55 
that can affect surrounding tissue. Common symptoms of a pituitary tumor compressive 56 
‘mass effect’ include visual impairment, headaches, neurological disorders and 57 
hypopituitarism caused by disruption of the hypothalamic-pituitary axis (Arafah & 58 
Nasrallah 2001; Melmed 2011). Based on their size, pituitary adenomas are classified 59 
as microadenomas (< 10mm), macroadenomas (>10mm) or giant adenomas (>40mm).  60 
Pituitary tumors usually present with monoclonal growth and can also be 61 
classified according to their cell type origin and hormone secretion. Thus, 62 
somatotropinomas secrete growth hormone (GH), prolactinomas secrete prolactin 63 
(PRL), thyrotropinomas secrete thyroid-stimulating hormone (TSH), and 64 
corticotropinomas secrete adrenocorticotropin hormone (ACTH).  In contrast, the non-65 
functioning pituitary adenomas do not produce any hormone and usually derive from 66 
gonadotropes (Kovacs et al. 2001; Syro et al. 2015).  67 
 68 
Prolactinomas 69 
Among functioning pituitary tumors, prolactinomas are the most frequently 70 
observed in the clinic (40%) (Ciccarelli et al. 2005).  Excessive PRL secretion by these 71 
tumors leads to hyperprolactinemia, which primarily affects gonadal/reproductive 72 
function, causing hypogonadism, galactorrhea, decreased libido and infertility both in 73 
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men and women. Large macroprolactinomas can also cause neurological symptoms 74 
due to compression of adjacent tissues.  75 
Prolactinomas are usually benign, and although some tumors show invasion 76 
into the parasellar compartment and/or sphenoid sinuses, malignant transformation 77 
and metastatic spread are extremely rare. Macroprolactinomas tend to be more 78 
aggressive and resistant to therapies than microprolactinomas (Wong et al. 2015a).  79 
Differences in prolactinoma incidence, tumor size and behavior have been 80 
described among genders. The prevalence of prolactinomas is higher in women during 81 
the fertile period (20-50 years), while the frequency is similar between sexes after the 82 
fifth decade of life (Colao et al. 2003; Gillam et al. 2006). Also, women usually present 83 
with microprolactinomas whereas men more often present with macroprolactinomas ( 84 
Delgrange et al. 1997; Nishioka et al. 2003). These differences have been associated 85 
to the earlier diagnosis in woman due to the readily detection of symptoms caused by 86 
high prolactin (amenorrea/ galactorrea) (Delgrange et al. 1997;Colao et al. 2003; 87 
Nishioka et al. 2003; Gillam et al. 2006). However, delayed diagnosis in men may not 88 
be the only explanation for the differences in tumor size, since young men also present 89 
with macroprolactinomas, and prolactinomas in men tend to be more aggressive, with 90 
higher proliferative indexes and lower rates of surgical cure, suggesting a sex-specific 91 
behavior for these tumors (Delgrange et al. 1997; Gillam MP & Molitch ME 2015).  92 
 93 
Prolactinoma treatment  94 
The major goals of treatment in patients with prolactinomas are to normalize 95 
serum PRL levels, to restore gonadal function, to reduce tumor size and to preserve or 96 
improve residual pituitary function. Prolactin secretion in the normal pituitary is tonically 97 
inhibited by hypothalamic dopamine through dopamine D2 receptors (Drd2) expressed 98 
on lactotroph cell membranes (Ben Jonathan & Hnasko 2001). The majority of 99 
prolactinomas retain an intact response to dopamine inhibition, therefore medical 100 
treatment with dopamine agonists (DAs), such as cabergolina and bromocriptine, 101 
Page 4 of 27
5 
 
represents the first line therapy for this tumors, including microprolactinomas, 102 
macroprolactinomas and giant prolactinomas (Wong et al. 2015b). Dopamine agonists 103 
are highly effective in achieving therapeutic aims with a favorable benefit/risk balance 104 
compared with surgical treatment.  105 
 106 
Dopamine agonist-resistant prolactinomas (DARPs) 107 
Despite the universal use of dopamine agonists and their high efficiency in 108 
reducing PRL levels and decreasing tumor size, there is a subset of prolactinomas (10-109 
15%) that do not respond appropriately to the treatment, even at high doses of DA 110 
(Vroonen et al. 2012). These tumors represent a major challenge for clinical 111 
management. DARPs are more prevalent in men than woman, occur most frequently 112 
as macroprolactinomas and tend to be invasive, exhibiting extension to the cavernous 113 
sinuses.  114 
The molecular mechanisms underlying the escape from dopaminergic 115 
regulation in DARPS are not fully elucidated. The main candidate thought to be 116 
responsible for resistance is the Drd2 itself. However, to date, no point mutation in the 117 
Drd2 gene has been identified in DARPs (Friedman et al. 1994; Molitch 2003; Gillam et 118 
al. 2006; Vroonen et al. 2012; Molitch 2014). Nevertheless, several mechanisms that 119 
lead to reduced Drd2 sensitivity were described in resistant prolactinomas, including 120 
evidence of decreased Drd2 mRNA expression, and differential expression of short and 121 
long Drd2 isoforms (Caccavelli et al. 1994; Vasilev et al. 2011; Shimazu et al. 2012); 122 
reduced Drd2 density and reduced dopamine binding sites in plasma membranes of 123 
DARP cells (Pellegrini et al. 1989). Alterations in dopamine signaling, such as 124 
decreased expression of the inhibitory alpha G protein subunit (Gαi2) have also been 125 
described (Caccavelli et al. 1996); as well as decreased expression of the nerve growth 126 
factor receptor (NGFR), which indirectly modulates Drd2 expression (Passos et al. 127 
2009). Histological studies on DARPs also revealed increased angiogenesis, cellular 128 
atypia (multinucleated cells, irregular nuclei) and increased proliferation index 129 
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measured by Ki67 staining, indicating an overall increase invasiveness (reviewed in 130 
(Gurlek et al. 2007)). 131 
  132 
Alternative treatments for DARPs 133 
At present, there is no alternative medical treatment for DARPs, and 134 
transsphenoidal surgery is indicated if the tumor is still resectable (Primeau et al. 2012; 135 
Smith et al. 2015). However, some aggressive prolactinomas recur post-operatively 136 
and show progressive growth, in which case, radiotherapy is the next therapeutic 137 
option, but with limited efficiency (Molitch 2014).  138 
The chemotherapy agent temozolomide (TMZ) has been recently used as a last 139 
resort therapy and showed a moderately successful response in large aggressive 140 
DARPs (Whitelaw et al. 2012; Liu et al. 2015; McCormack et al. 2011). However the 141 
efficacy of TMZ therapy in aggressive pituitary adenomas remains controversial (Bruno 142 
et al. 2015) and clinical trials are now necessary to establish the indications, doses, 143 
and duration of TMZ administration to more accurately determine the efficacy of this 144 
agent. 145 
New therapeutic approaches are necessary for those prolactinomas that are 146 
resistant to conventional treatments. Few reports of experimental treatments can be 147 
found in the literature and show variable effectiveness in pre-clinical and in vitro 148 
models. For instance, treatment with somatostatin receptor (SSTR) analogs failed to 149 
inhibit prolactin secretion by cultured cells derived from DARPs (Fusco et al. 2008) 150 
despite the expression of all subtypes of SSTR in human prolactinomas (Jaquet et al. 151 
1999).  152 
 Based on the counteracting effects of estradiol on dopamine action in 153 
lactotrophs, targeting of the estrogen receptor with tamoxifen was evaluated in the pre-154 
cabergoline era in patients with bromocriptine-resistant prolactinomas, but only a 155 
moderated reduction in PRL levels was observed (Volker et al. 1982). A novel anti-156 
estrogen agent, fulvestrant, also reduced PRL secretion in pituitary cell lines, and 157 
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decreased tumor growth and serum PRL in estrogen-induced prolactinomas in rats 158 
(Cao et al. 2014).  159 
 160 
In the search for new therapeutic targets for DARPs 161 
Studies in animal models of prolactinomas with altered sensitivity to DA, such 162 
as the estrogen induced prolactinomas in rats and the Drd2 knock-out mice (Drd2-/-) 163 
have been very helpful to identify molecular pathways altered in these tumors and to 164 
test potential future therapies. Many of these studies suggest that the deregulation of 165 
local growth factors and extracellular matrix remodeling participate in the pathogenesis 166 
of prolactinomas by promoting cell proliferation, angiogenesis and invasiveness (Paez-167 
Pereda et al. 2005; Cristina et al. 2005; Cristina et al. 2007; Recouvreux et al. 2013).  168 
Transforming growth factor beta 1 (TGFβ1), a well-known inhibitor in lactotroph 169 
physiology, has been recently identified as a novel target for the development of new 170 
therapies in resistant prolactinomas.  171 
 172 
The complexity of the TGFβ system and biology  173 
TGFβs are multifunctional cytokines known to play crucial regulatory roles in 174 
cellular proliferation and differentiation, angiogenesis, extracellular matrix modification 175 
and immunomodulation (Yoshinaga et al. 2008), and have powerful effects on 176 
embryogenesis, development and tissue homeostasis (Heldin et al. 2009; Galvin-177 
Burgess et al. 2013; Itoh et al. 2014). The TGFβ family comprises more than 30 highly 178 
pleiotropic molecules including activins, inhibins, nodal, bone morphogenetic proteins 179 
(BMPs), the anti-muellerian hormone (AMH), and several growth and differentiation 180 
factors (GDFs) among others (Derynck & Akhurst 2007). Three isoforms of TGFβ have 181 
been identified (TGFβ1, 2, and 3).  182 
The importance of TGFβ1 is clearly demonstrated by the fact that TGFβ1 null 183 
mutation causes excessive inflammatory response and early death (Kulkarni et al. 184 
1993). On the contrary, an excess of TGFβ1 activity is associated to connective tissue 185 
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diseases, fibrosis and inflammation, cirrhosis, arthritis and sclerosis, cardiovascular 186 
diseases and cancer, making TGFβ an interesting target for therapeutic research 187 
(Pohlers et al. 2009; Doyle et al. 2012; Akhurst & Hata 2012).  188 
Nearly all cell types are sensitive to TGFβ1, but TGFβ action is highly 189 
dependent on cell type, developmental stage, physiological- pathological conditions, 190 
interaction with components of the extracellular matrix and, once bond to its receptor, 191 
interaction with other signaling pathways.  192 
The potent biological activity of TGFβ1 is tightly regulated at different levels, 193 
including its synthesis, secretion, storage and activation. The three TGFβ isoforms are 194 
synthesized as homodimeric precursor molecules that contain a pro-peptide sequence, 195 
called latency associated peptide (LAP), and the functional mature TGFβ sequence 196 
(Figure 1. 1). After proteolytic processing by furin within the trans-golgi, LAP remains 197 
associated with the mature TGFβ by non-covalent interactions in a small latent 198 
complex (Figure 1. 2). While in the endoplasmic reticulum, LAP is linked, by disulfide 199 
bonds, with a latent TGFβ binding protein (LTBP) (Figure 1. 3). LTBPs belong to a 200 
family of large secretory extracellular matrix (ECM) glycoproteins. Although LTBPs are 201 
not required for maintenance of TGFβ latency, they facilitate the secretion, storage, 202 
and activation of the TGFβ–LAP complex (Rifkin 2005).  203 
TGFβ is secreted as part of this large latent TGFβ complex (LLC), (Figure 1. 3), 204 
and is incorporated as component of the ECM, which acts as a cytokine reservoir 205 
(Figure 1. 4). Trapped in the ECM, TGFβ remains latent because of persistent binding 206 
of LAP and must undergo a highly regulated activation process by which mature 207 
cytokine is released from its latent complex to enable the active form to bind and signal 208 
through its receptor (Figure 1. 5). Latent TGFβ activation is a crucial event in governing 209 
the cytokine biological function and availability in the ECM (Annes et al. 2003; Annes et 210 
al. 2004; Rifkin 2005).  211 
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Several latent TGFβ1 activators have been described, including proteases 212 
(such as plasmin, matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 213 
(MMP9), BMP-1, thrombospondin-1 (TSP-1), kallikrein 1 (KLK1), integrins αvβ6 and 214 
αvβ8, and reactive oxygen species (ROS) or pH changes in the local environment, 215 
among others. However, their individual biological importance in releasing TGFβ1 from 216 
its latent complex and their local regulation in different tissues are not fully understood 217 
(Annes et al. 2003; Annes et al. 2004; Yoshinaga et al. 2008). Since all these factors 218 
are related to ECM perturbations, the latent TGFβ complex has been postulated as a 219 
“sensor” of environment disturbances (Annes et al. 2003). 220 
Once TGFβ1 is released from the ECM, the active cytokine binds to its 221 
transmembrane receptor, the type II TGFβ receptor (TβRII),  a constitutively active 222 
kinase that recruits and phosphorylates TβRI (type I TGFβ receptor) forming a 223 
heterotetrameric complex of serine/threonine kinase receptors containing two type I 224 
and two type II subunits (Figure 1, 6). Next, TβRI phosphorylates the downstream 225 
receptor-associated Smads (R-Smads: Smad2/Smad3), which form a heteromeric 226 
complex with Smad4, and translocate to the nucleus to regulate the transcription of 227 
target genes (Figure 1. 7). Additionally, an inhibitory Smad, Smad7, competes with the 228 
Smad2/3 for binding to the activated TβRI, thereby exerting a negative effect on 229 
TGFβ/Smad signaling (Shi & Massague 2003; Han et al. 2015).  230 
This pathway is known as “the canonical” TGFβ signaling pathway. However, 231 
TGFβ can also signal through smad-independent pathways, including the mitogen-232 
activated protein kinases (ERK1/2, JNK, p38), small GTP-binding proteins (Ras, RhoA, 233 
Rac1, CDC42, mTOR), the NF-κB pathway and Wnt/β-catenin pathway, the AKT/PKB 234 
pathway and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) ( Attisano & Wrana 235 
2002; Derynck & Zhang 2003; Moustakas & Heldin 2005).  236 
As a multifunctional cytokine with powerful effects on cell proliferation, cellular 237 
migration and inflammation, TGFβ signaling has been targeted for drug development 238 
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and numerous strategies have proceeded through preclinical to clinical trials (reviewed 239 
in (Akhurst & Hata 2012)). 240 
 241 
 - TGFβ1 in the pituitary: a brief history  242 
The earliest publications on TGFβ1 action in the pituitary date from the late 80s 243 
and early 90s (Ying et al. 1986; Mueller & Kudlow 1991). Dr. Sarkar and col were the 244 
first to demonstrate local TGFβ1 mRNA and protein expression in the pituitary gland, 245 
and the inhibitory action of TGFβ1 on prolactin secretion and lactotrophic growth in 246 
1992 (Sarkar et al. 1992).  Although these first evidences were found in animal models 247 
(rat), TGFβ1 and TβRII expression were promptly found to be expressed in human 248 
pituitaries (Halper et al. 1992; Fujiwara et al. 1995), as well as in human 249 
pituitary adenomas  (Fujiwara et al. 1995; Jin et al. 1997).  250 
The main physiological modulators of lactotroph function are dopamine and 251 
estradiol, which exert inhibitory and stimulatory actions, respectively (Ben Jonathan & 252 
Hnasko 2001). The pro-mitotic effect of estradiol (pharmacological doses) and its role 253 
in prolactinoma induction is very well described in the literature (Heaney et al. 2002). 254 
However, estrogens also participate in the lactotroph cell turnover in normal pituitary 255 
glands, sensitizing lactotroph cells to apoptotic stimuli. Therefore the effect of estradiol 256 
on lactotroph function depends on the dose and normal/tumoral condition of the cells 257 
(Pisera et al. 2004; Zaldivar et al. 2009; Jaita et al. 2015). Interestingly, dopamine and 258 
estradiol also regulate the expression of both TGFβ1 and its receptor, but in opposite 259 
ways. Thus, while estrogen stimulation increases serum PRL levels and lactotroph 260 
proliferation, it decreases the expression of TGFβ1 in the anterior pituitary. On the 261 
contrary, dopamine, acting through the Drd2, up-regulates TGFβ1 expression and 262 
secretion in vivo and in vitro, with a concomitant reduction in the proliferation rate of 263 
lactotrophs. Moreover, it has been proposed that TGFβ1 partially mediates the 264 
inhibitory effect of dopamine on lactotroph proliferation (Sarkar et al. 2005). Our group 265 
has recently described that the amount of pituitary active TGFβ1 is also locally 266 
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regulated by dopamine and estradiol treatment in mice, and moreover we found an 267 
inverse correlation between active TGFβ1 levels and serum PRL (Recouvreux et al. 268 
2011). It is worth noting that less than 8% of total pituitary TGFβ1 was found in the 269 
active form, similar to what has been described in other tissues (Yoshinaga et al. 270 
2008). This underscores the tightly regulation of the latent TGFβ activation process.   271 
Other important factor regulating lactotroph homeostasis is PRL itself, acting through 272 
the PRL receptor (PRLR). It has been shown that endogenous PRL exerts 273 
paracrine/autocrine antiproliferative and proapoptotic effects on lactotrophs, and 274 
moreover, knock-out mice lacking PRLR develop prolactinomas, further demonstrating 275 
the important role of PRL in the negative feedback on lactotroph function (Schuff et al. 276 
2002; Ferraris et al. 2012; Ferraris et al. 2014).  277 
Whether PRL can as well regulate TGFβ1 expression or function in the pituitary gland 278 
is an open question that has not yet been addressed.  279 
 280 
Alterations in the components of the TGFβ1 system during prolactinoma 281 
development 282 
 283 
- Evidences of TGFβ1 alterations in estradiol-induced prolactinomas in rats 284 
The estrogen-treated rat is a well-known model for prolactinoma development 285 
with increased pituitary weight, hyperprolactinemia, lactotroph hyperplasia and reduced 286 
dopaminergic action at the pituitary level (Heaney et al. 1999; Heaney et al. 2002b). 287 
Furthermore, estradiol treatment decreases pituitary TGFβ1 and TβRII mRNA and 288 
protein, together with an increase in PRL levels (Sarkar et al. 1992; Pastorcic et al. 289 
1995; De et al. 1996) (Figure 2). Therefore, the inhibition of TGFβ1 and TβRII might 290 
cooperate in the development of prolactinomas induced by estradiol (Hentges & Sarkar 291 
2001). In agreement with this idea, pituitary tumorigenesis induced by estrogen 292 
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treatment is greatly accelerated in TβRII heterozygous knockout mice (TβRII+/-) where 293 
the expression of TβRII is markedly reduced (Shida et al. 1998).  294 
 295 
- TGFβ1 alterations in the prolactinoma development in Drd2 -/- mice 296 
Another well characterized model to study prolactinoma development are the 297 
transgenic knock out mice lacking functional Drd2 (Drd2-/-). This model represents an 298 
excellent model to mimick dopamine agonist-resistance. Because of the absence of 299 
inhibitory dopaminergic control, these mice display chronic hyperprolactinemia and 300 
lactotroph hyperplasia (Kelly et al. 1997; Diaz-Torga et al. 2002; Cristina et al. 2006), 301 
but the loss of dopamine inhibition has deeper effect on pituitary function in female than 302 
in male mice (Saiardi et al. 1997; Diaz-Torga et al. 2002). In females the increase in 303 
serum prolactin levels is much more pronounced than in males, and females develop 304 
lactotroph hyperplasia from 6 month onwards, while age-matched Drd2-deficient males 305 
develop pituitary lactotroph adenomas at 17 to 20 months of age (Asa et al. 1999).  306 
Interestingly, active and total TGFβ1 levels, as well as TβRII and LTBP1 307 
expression are reduced in Drd2-/- pituitaries compared to controls (wild type or wt), 308 
highlighting the stimulatory role of dopamine on pituitary TGFβ1 system (Recouvreux et 309 
al. 2011) (Figure 2). On the other hand, the impact of the chronic loss of dopaminergic 310 
tone on the TGFβ1 system was also stronger in females, evidenced by the 311 
downregulation of several putative TGFβ1 activators (MMP2, MMP9, MT1-MMP, 312 
thrombospondin-1 and kallikrein) as well as the decreased expression of TGFβ1 target 313 
genes observed only in females (Drd2-/- vs. their wt counterpart). In this model we 314 
found sex differences in the regulation of the TGFβ1 system: males express higher 315 
levels of several components of the TGFβ1 system, and it could be due to the lower 316 
serum estradiol levels present in males, as estradiol negatively controls most of the 317 
components of the system (Recouvreux et al. 2013). We suggest that stronger pituitary 318 
TGFβ1 system could protect males from excessive lactotroph proliferation and 319 
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prolactinoma development. Then, sex differences found in the regulation of the TGFβ1 320 
system could explain sex differences found in the incidence of prolactinoma 321 
development in this model. 322 
 323 
- TGFβ1 alterations in human pituitary tumors 324 
In humans the expression of several components of the TGFβ signaling 325 
pathway was recently compared in five normal human anterior pituitaries, 29 invasive 326 
nonfunctioning pituitary adenomas (NFPAs) and 21 noninvasive NFPAs (Zhenye et al. 327 
2014). This report demonstrated that TGFβ1 mRNA expression and p-Smad3 protein 328 
levels gradually decreased, while Smad7 mRNA levels gradually increased from 329 
normal anterior pituitaries to noninvasive NFPAs and invasive NFPAs. The authors 330 
concluded that the activity of TGFβ signaling would be limited during tumor 331 
development.  332 
Recent work also described a significant down-regulation of the TGFβ1/Smad 333 
signaling cascade in 12 cases of DARPs compared to normal human anterior 334 
pituitaries. The authors showed that TGFβ1 mRNA levels, and Smad2 and Smad3 335 
mRNA and protein expression were significantly decreased in human prolactinomas (Li 336 
et al. 2015) (Figure 2). 337 
 338 
Overall, decreased TGFβ1 activity and decreased expression of different 339 
components of the TGFβ1 system have been described in animal models of 340 
prolactinomas as well as in human prolactinomas. Taking into account that TGFβ1 341 
inhibits lactotroph proliferation and PRL synthesis and secretion, we speculate that 342 
recovering local TGFβ1 activity could contribute to revert the adenoma development 343 
and to normalize prolactinemia.  344 
  345 
- Recovery of local TGFβ1 activity. Successful treatment in an experimental 346 
model of prolactinoma 347 
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  348 
Thrombospondin-1 (TSP1) is one of the main physiologic latent TGFβ1 349 
activators in vitro and in vivo (Schultz-Cherry et al. 1994). TSP1 is a large 350 
multifunctional matrix glycoprotein involved in cell growth, adhesion, migration (Lawler 351 
2002). TSP1 also functions as an endogenous antiangiogenic factor, inhibiting the 352 
proliferation and migration of endothelial cells by interaction with its cell surface 353 
receptor CD36 and by antagonizing VEGF activity (Lawler & Lawler 2012).  354 
Based on the CD36-binding peptide sequence from TSP-1, small-molecules were 355 
developed to mimic TSP-1 antiangiogenic properties (Haviv et al. 2005). Several of 356 
these new drugs were able to slow tumor growth in preclinical models (Anderson et al. 357 
2007; Yang et al. 2007; Garside et al. 2010). Among them, ABT-510 and ABT-898 358 
(Abbott Laboratories), two of such TSP1 analogs, were assayed in several solid tumors 359 
(Haviv et al. 2005). ABT-510 was evaluated in phase II clinical trials for the treatment of 360 
head and neck cancer, non-small cell lung cancer, lymphoma, and renal cell carcinoma 361 
(Haviv et al. 2005; Ebbinghaus et al. 2007; Markovic et al. 2007; Yang et al. 2007; 362 
Gordon et al. 2008; Nabors et al. 2010). The second-generation TSP-1 synthetic 363 
analogue, ABT-898, was found to have greater potency than ABT-510 and is expected 364 
to have greater efficacy than the other available TSP-1-mimetic peptides (Garside et al. 365 
2010; Campbell et al. 2011) due to its lower clearance rate.   366 
Immunoreactive TSP-1 is present in the anterior pituitary, particularly in 367 
endothelial cells (Burns & Sarkar 1993), and TSP-1 levels and its antiangiogenic effect 368 
are reduced in prolactinomas induced by estradiol in rats (Sarkar et al. 2007) and in the 369 
hyperplastic pituitaries of Drd2-/- mice (Recouvreux et al. 2013). TSP-1 expression was 370 
also found down-regulated in invasive vs. non-invasive prolactinomas in humans (Jiang 371 
et al. 2012).  372 
Given that: 1) TSP1 is an antiangiogenic factor, 2) TSP1 expression is reduced 373 
during prolactinoma development, 3) TSP1 is a known TGFβ1 activator, 4) TGFβ1 374 
activity is also reduced during the development of prolactinomas, and 5) TGFβ1 is an 375 
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inhibitory factor of lactotroph proliferation and synthesis; we speculated that treatments 376 
that improve pituitary TSP-1 and/or TGFβ1 activities could reduce the progression of 377 
prolactinomas.  378 
 We first evaluated whether the TSP1 analogs were able to activate TGFβ1 in 379 
the pituitary.  In fact, an in vivo short term treatment (100 mg/kg ABT-510, ip, 30 min) 380 
enhanced the biological activity of pituitary TGFβ1, with a concomitant reduction in 381 
serum prolactin levels (Recouvreux et al. 2012). Notably, same effect was observed 382 
after short term treatment with ABT-510 in female rats carrying prolactinoma induced 383 
by chronic estradiol treatment. We next evaluated whether an in vivo treatment for two 384 
weeks with the TSP1 analogs could counteract the development of estradiol-induced 385 
prolactinomas in rats. ABT-510 and ABT-898 treatment (100mg/kg ip, thrice a week for 386 
two weeks) significantly decreased pituitary tumor size, reduced tissue angiogenesis 387 
and pituitary proliferation markers, as well as serum prolactin levels, in female rats with 388 
prolactinomas induced by chronic treatment with estradiol (Recouvreux et al. 2012). 389 
Furthermore, ABT-510 and ABT-898 treatment markedly increased active TGFβ1 390 
content, measured by ELISA within the tumors. The increase in cytokine activation was 391 
also reflected in the recovery of intrapituitary pSMAD2/3 expression (Figure 3). Besides 392 
from the well-known antiangiogenic effect of these TSP-1 mimetic peptides, the 393 
improvement of the local TGFβ1 biological activity, most likely contributed to the 394 
reduction in serum prolactin and in the inhibition of prolactinoma growth.  395 
 396 
- Overall conclusions and Perspectives  397 
 398 
Prolactinomas are the most frequent pituitary tumors in adults accounting for 399 
60% of all functioning pituitary tumors (Ciccarelli et al. 2005). Even though 400 
prolactinomas are usually benign and in most cases respond well to treatment with 401 
dopaminergic agents, 15% of these tumors are resistant to classical therapy, become 402 
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invasive and aggressive, and require extirpation. The mechanisms underlying the 403 
escape from dopaminergic regulation in DARPS are not fully understood, and the main 404 
candidate to be responsible for resistance is the Drd2 itself. Since TGFβ1 mediates, at 405 
least partially, the inhibitory action exerted by dopamine on lactotrophs, and reduced 406 
TGFβ1 activity is a common feature of prolactinoma development, treatments that 407 
improve pituitary TGFβ1 activity represent a rational approach to develop alternative 408 
therapies for  DARPs. Supporting this, we provide evidence of the effectiveness of a 409 
treatment with the small TSP1-analog peptides ABT-510 and ABT-898 to restore 410 
TGFβ1 activity and to counteract prolactinoma development in rats.  411 
 412 
Taken together the data summarized here, the recovery of TGFβ1 activity 413 
emerges as a novel therapeutic target for treatment of dopamine agonist resistant 414 
prolactinomas.  415 
 416 
417 
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FIGURE LEGENDS 
 
Figure 1:  The biology of TGFβ system 
TGFβ is synthesized as homodimeric precursor containing a pro-peptide sequence 
LAP, (1), and then processed by furin.  LAP remains associated with the mature TGFβ by 
non-covalent interactions in a small latent complex (2), which in turn is linked by disulfide 
bonds to one of the latent TGFβ binding proteins (LTBP1-4) (3). TGFβ is secreted as part of 
this large latent TGFβ complex (LLC) (3), and it is incorporated as component of the 
extracellular matrix (ECM), which acts as a reservoir of the cytokine (4). TGFβ must undergo 
a highly regulated activation process by which mature cytokine is released (5) to enable 
binding to its receptor complex (TβRI and TβRII) (6) and signal through Smad2/Smad3 
pathway (7). Known TGFβ activators are listed in the upper left.  
 
Figure 2:  Alterations of TGFβ1 system in prolactinomas  
Decreased expression of different components of pituitary TGFβ1 system in prolactinoma 
models are represented with down-pointed arrows. Gray arrows indicate findings in human 
prolactinoma specimens; black arrows indicate findings in Drd2-/- mice; white arrows indicate 
findings in estradiol induced prolactinomas in rats.  
 
Figure 3: Recovery of TGFβ1 activity emerges as a novel therapeutic target for 
treatment of dopamine agonist resistant prolactinomas. Treatment with 
Thrombospondin-1 analogs (ABT-510, ABT-898) recover pituitary TGFβ1 activity, reduce 
tumor size, tumor angiogenesis and proliferation markers, as well as serum prolactin in 
estradiol-induced prolactinomas in female rats.   
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Figure 2:  Alterations of TGFβ1 system in prolactinomas. Decreased expression of different components of 
pituitary TGFβ1 system in prolactinoma models are represented with down-pointed arrows. Gray arrows 
indicate findings in human prolactinoma specimens; black arrows indicate findings in Drd2-/- mice; white 
arrows indicate findings in estradiol induced prolactinomas in rats.  
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Figure 3: Recovery of TGFβ1 activity emerges as a novel therapeutic target for treatment of dopamine 
agonist resistant prolactinomas. Treatment with Thrombospondin-1 analogs (ABT-510, ABT-898) recover 
pituitary TGFβ1 activity, reduce tumor size, tumor angiogenesis and proliferation markers, as well as serum 
prolactin in estradiol-induced prolactinomas in female rats.    
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